» Articles » PMID: 16354677

Inhibition of SIRT1 Catalytic Activity Increases P53 Acetylation but Does Not Alter Cell Survival Following DNA Damage

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2005 Dec 16
PMID 16354677
Citations 239
Authors
Affiliations
Soon will be listed here.
Abstract

Human SIRT1 is an enzyme that deacetylates the p53 tumor suppressor protein and has been suggested to modulate p53-dependent functions including DNA damage-induced cell death. In this report, we used EX-527, a novel, potent, and specific small-molecule inhibitor of SIRT1 catalytic activity to examine the role of SIRT1 in p53 acetylation and cell survival after DNA damage. Treatment with EX-527 dramatically increased acetylation at lysine 382 of p53 after different types of DNA damage in primary human mammary epithelial cells and several cell lines. Significantly, inhibition of SIRT1 catalytic activity by EX-527 had no effect on cell growth, viability, or p53-controlled gene expression in cells treated with etoposide. Acetyl-p53 was also increased by the histone deacetylase (HDAC) class I/II inhibitor trichostatin A (TSA). EX-527 and TSA acted synergistically to increase acetyl-p53 levels, confirming that p53 acetylation is regulated by both SIRT1 and HDACs. While TSA alone reduced cell survival after DNA damage, the combination of EX-527 and TSA had no further effect on cell viability and growth. These results show that, although SIRT1 deacetylates p53, this does not play a role in cell survival following DNA damage in certain cell lines and primary human mammary epithelial cells.

Citing Articles

Sirtuin-1 Regulates Mitochondrial Calcium Uptake Through Mitochondrial Calcium Uptake 1 (MICU1).

Zhang X, Liu S, Su Y, Zhang L, Guo T, Wang X Life (Basel). 2025; 15(2).

PMID: 40003583 PMC: 11856031. DOI: 10.3390/life15020174.


Regulation of HDAC6 Catalytic Activity in Cancer: The Role of Post-Translational Modifications and Protein-Protein Interactions.

Asaad L, Pepperrell B, McErlean E, Furlong F Int J Mol Sci. 2025; 26(3).

PMID: 39941046 PMC: 11818932. DOI: 10.3390/ijms26031274.


Sirtuin Proteins and Memory: A Promising Target in Alzheimer's Disease Therapy?.

Fernandez F, Griffiths L, Sutherland H, Cole M, Fitton J, Winberg P Nutrients. 2024; 16(23).

PMID: 39683482 PMC: 11644011. DOI: 10.3390/nu16234088.


The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy.

Tang Y, Ju W, Liu Y, Deng Q Front Pharmacol. 2024; 15:1469830.

PMID: 39403142 PMC: 11471651. DOI: 10.3389/fphar.2024.1469830.


EX527, a sirtuins 1 inhibitor, sensitizes T-cell leukemia to death receptor-mediated apoptosis by downregulating cellular FLICE inhibitory protein.

Guo R, Wei Y, Du Y, Liu L, Zhang H, Ren R Cancer Biol Ther. 2024; 25(1):2402588.

PMID: 39286953 PMC: 11409494. DOI: 10.1080/15384047.2024.2402588.


References
1.
Vaziri H, Dessain S, Ng Eaton E, Imai S, Frye R, Pandita T . hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001; 107(2):149-59. DOI: 10.1016/s0092-8674(01)00527-x. View

2.
Luo J, Nikolaev A, Imai S, Chen D, Su F, SHILOH A . Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001; 107(2):137-48. DOI: 10.1016/s0092-8674(01)00524-4. View

3.
Barlev N, Liu L, Chehab N, Mansfield K, Harris K, Halazonetis T . Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell. 2002; 8(6):1243-54. DOI: 10.1016/s1097-2765(01)00414-2. View

4.
Tyner S, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H . p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002; 415(6867):45-53. DOI: 10.1038/415045a. View

5.
Lai S, Perng R, Hwang J . p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci. 2000; 7(1):64-70. DOI: 10.1007/BF02255920. View